Pancreatic Cancer Research

ResearcherUniversity of LiverpoolActive in the last 2 years

Christopher Michael Halloran

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-5471-4178; OpenAlex author ID A5081306432. Sources: ClinicalTrials.gov.

Their work

Papers
44 (first author 1, last author 5)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
1
Collaborators
183
Papers, trials and grants by year

2012: 1 paper · 2013: none · 2014: 2 papers · 2015: 2 papers, 1 trial · 2016: 2 papers · 2017: 1 paper · 2018: 6 papers · 2019: 4 papers · 2020: 4 papers · 2021: 1 paper · 2022: 4 papers · 2023: 2 papers · 2024: 4 papers · 2025: 7 papers · 2026: 4 papers

Papers 44

  1. Risk-stratified surveillance for individuals in the UK at high risk of developing pancreatic cancer: Outcomes from the European Registry of Hereditary Pancreat… Last author DOI 10.1016/j.ejca.2026.116592↗
  2. The benefit of deep genomic testing for asymptomatic high-risk individuals undergoing surveillance for pancreatic adenocarcinoma: European registry for heredit… Last author DOI 10.1016/j.neo.2026.101316↗
  3. Real-world outcomes following adjuvant chemotherapy for resected pancreatic cancer in a centralised oncology service. Co-author DOI 10.1038/s41416-026-03341-0↗
  4. NQO1 as a predictor of response to adjuvant GemCap treatment for pancreatic cancer. Co-author DOI 10.1093/jnci/djaf345↗
  5. Cost-Effectiveness of Biomarker-Associated Early Pancreatic Cancer Detection in New-Onset Diabetes. Co-author DOI 10.1001/jamanetworkopen.2025.38031↗
  6. GATA6 immunohistochemistry and prognosis after surgical resection of pancreatic adenocarcinoma: results from the ESPAC-4 trial. Co-author DOI 10.1016/j.esmogo.2025.100138↗
  7. Neoadjuvant treatment versus upfront surgery in borderline resectable and resectable pancreatic ductal adenocarcinoma: meta-analysis. Co-author DOI 10.1093/bjsopen/zrae172↗
  8. Prevalence of New-Onset Diabetes in Patients Undergoing Pancreatic Surgery and the Association of Glucose Dysregulation With Complications in Pancreatic Cancer. Co-author DOI 10.1097/as9.0000000000000584↗
  9. Development and validation of a diagnostic prediction model for pancreatic ductal adenocarcinoma: VAPOR 1, protocol for a prospective multicentre case-control … Co-author DOI 10.1136/bmjopen-2024-094505↗
  10. European Registry of Hereditary Pancreatic Diseases (EUROPAC): protocol for primary and secondary screening in individuals with inherited pancreatic disease sy… Last author DOI 10.1136/bmjopen-2025-100027↗
  11. Pancreatic Adenocarcinoma: Long-Term Outcomes of Adjuvant Therapy in the ESPAC4 Phase III Trial. Co-author DOI 10.1200/jco.24.01118↗
  12. Macrophage-fibroblast JAK/STAT dependent crosstalk promotes liver metastatic outgrowth in pancreatic cancer. Co-author DOI 10.1038/s41467-024-47949-3↗
  13. Efferocytosis reprograms the tumor microenvironment to promote pancreatic cancer liver metastasis. Co-author DOI 10.1038/s43018-024-00731-2↗
  14. Author Correction: Efferocytosis reprograms the tumor microenvironment to promote pancreatic cancer liver metastasis. Co-author DOI 10.1038/s43018-024-00751-y↗
  15. Mesothelin Secretion by Pancreatic Cancer Cells Co-opts Macrophages and Promotes Metastasis. Co-author DOI 10.1158/0008-5472.can-23-1542↗
  16. Determination of "borderline resectable" pancreatic cancer - A global assessment of 30 shades of grey. Co-author DOI 10.1016/j.hpb.2023.07.883↗
  17. Immediate surgery compared with short-course neoadjuvant gemcitabine plus capecitabine, FOLFIRINOX, or chemoradiotherapy in patients with borderline resectable… Co-author DOI 10.1016/s2468-1253(22)00348-x↗
  18. Blood levels of adiponectin and IL-1Ra distinguish type 3c from type 2 diabetes: Implications for earlier pancreatic cancer detection in new-onset diabetes. Co-author DOI 10.1016/j.ebiom.2021.103802↗
  19. United Kingdom Early Detection Initiative (UK-EDI): protocol for establishing a national multicentre cohort of individuals with new-onset diabetes for early de… Co-author DOI 10.1136/bmjopen-2022-068010↗
  20. Chemotherapy-induced infiltration of neutrophils promotes pancreatic cancer metastasis via Gas6/AXL signalling axis. Co-author DOI 10.1136/gutjnl-2021-325272↗
  21. Recent advances in understanding pancreatic cancer. Last author DOI 10.12703/r/11-9↗
  22. hENT1 Predicts Benefit from Gemcitabine in Pancreatic Cancer but Only with Low CDA mRNA. Co-author DOI 10.3390/cancers13225758↗
  23. Prognostic value of 18FDG PET/CT volumetric parameters in the survival prediction of patients with pancreatic cancer. Co-author DOI 10.1016/j.ejso.2020.02.002↗
  24. International consensus guidelines on surveillance for pancreatic cancer in chronic pancreatitis. Recommendations from the working group for the international … Co-author DOI 10.1016/j.pan.2020.05.011↗
  25. Early detection of pancreatic cancer. Co-author DOI 10.1016/s2468-1253(19)30416-9↗
  26. Cathepsin D Expression and Gemcitabine Resistance in Pancreatic Cancer. Co-author DOI 10.1093/jncics/pkz060↗
  27. Patterns of Recurrence After Resection of Pancreatic Ductal Adenocarcinoma: A Secondary Analysis of the ESPAC-4 Randomized Adjuvant Chemotherapy Trial. Co-author DOI 10.1001/jamasurg.2019.3337↗
  28. Identification of Cystic Lesions by Secondary Screening of Familial Pancreatic Cancer (FPC) Kindreds Is Not Associated with the Stratified Risk of Cancer. Co-author DOI 10.1038/s41395-018-0395-y↗
  29. The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1097/sla.0000000000002557↗
  30. Response to Comment on "The Impact of Positive Resection Margins on Survival and Recurrence Following Resection and Adjuvant Chemotherapy for Pancreatic Ductal… Co-author DOI 10.1097/sla.0000000000003371↗
  31. Expression of dihydropyrimidine dehydrogenase (DPD) and hENT1 predicts survival in pancreatic cancer. Co-author DOI 10.1038/s41416-018-0004-2↗
  32. Intratumoural expression of deoxycytidylate deaminase or ribonuceotide reductase subunit M1 expression are not related to survival in patients with resected pa… Co-author DOI 10.1038/s41416-018-0005-1↗
  33. Immune Cell and Stromal Signature Associated With Progression-Free Survival of Patients With Resected Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1053/j.gastro.2018.08.009↗
  34. Pancreatic Cancer and FOLFIRINOX: Should We Resect All Responders? First author DOI 10.1097/sla.0000000000002026↗
  35. Cytoplasmic HuR Status Predicts Disease-free Survival in Resected Pancreatic Cancer: A Post-hoc Analysis From the International Phase III ESPAC-3 Clinical Tria… Co-author DOI 10.1097/sla.0000000000002088↗
  36. PET-PANC: multicentre prospective diagnostic accuracy and health economic analysis study of the impact of combined modality 18fluorine-2-fluoro-2-deoxy-d-gluco… Co-author DOI 10.3310/hta22070↗
  37. Comparison of adjuvant gemcitabine and capecitabine with gemcitabine monotherapy in patients with resected pancreatic cancer (ESPAC-4): a multicentre, open-lab… Co-author DOI 10.1016/s0140-6736(16)32409-6↗
  38. The impact of diabetes mellitus on survival following resection and adjuvant chemotherapy for pancreatic cancer. Co-author DOI 10.1038/bjc.2016.277↗
  39. Association of genetic polymorphisms with survival of pancreatic ductal adenocarcinoma patients. Co-author DOI 10.1093/carcin/bgw080↗
  40. Incidence of post-ERCP pancreatitis from direct pancreatic juice collection in hereditary pancreatitis and familial pancreatic cancer before and after the intr… Co-author DOI 10.1097/mpa.0000000000000246↗
  41. Biomarkers for early diagnosis of pancreatic cancer. Co-author DOI 10.1586/17474124.2015.965145↗
  42. Pancreatic cancer hENT1 expression and survival from gemcitabine in patients from the ESPAC-3 trial. Co-author DOI 10.1093/jnci/djt347↗
  43. Serum cytokine biomarker panels for discriminating pancreatic cancer from benign pancreatic disease. Co-author DOI 10.1186/1476-4598-13-114↗
  44. Nanotechnology advances in upper gastrointestinal, liver and pancreatic cancer. Last author DOI 10.1586/egh.12.13↗

Trials 1

  1. Cattell-Warren Versus Blumgart Techniques of Pancreatico-jejunostomy Following Pancreato-duodenectomy Principal investigator NCT02457156↗

Closest collaborators

The 25 strongest of 183 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Paula Ghaneh · 31 shared papers, 2014–2026 · strength 3.67
  2. William Greenhalf · 23 shared papers, 2014–2026 · strength 2.87
  3. Eithne Costello · 21 shared papers, 2012–2026 · strength 2.37
  4. John P. Neoptolemos · 24 shared papers, 2012–2026 · strength 2.16
  5. Daniel H. Palmer · 18 shared papers, 2014–2025 · strength 1.88
  6. Lucy S. Oldfield · 7 shared papers, 2020–2026 · strength 1.28
  7. Michael C. Schmid · 6 shared papers, 2022–2025 · strength 1.10
  8. Ainhoa Mielgo · 6 shared papers, 2022–2025 · strength 1.10
  9. Martyn Charles Stott · 5 shared papers, 2022–2026 · strength 1.10
  10. Markus Wolfgang Büchler · 13 shared papers, 2014–2025 · strength 1.03
  11. Thilo Hackert · 8 shared papers, 2016–2026 · strength 0.93
  12. Gaia Bellomo · 5 shared papers, 2022–2024 · strength 0.84
  13. Annabelle Boughey · 3 shared papers, 2025–2026 · strength 0.83
  14. Stephen P. Pereira · 6 shared papers, 2018–2026 · strength 0.75
  15. Daniel H. Palmer · 3 shared papers, 2025–2026 · strength 0.73
  16. Robert Peter Jones · 5 shared papers, 2019–2024 · strength 0.73
  17. Juan W. Valle · 9 shared papers, 2014–2025 · strength 0.69
  18. Markus M. Lerch · 10 shared papers, 2016–2021 · strength 0.66
  19. Valeria Quaranta · 4 shared papers, 2022–2024 · strength 0.64
  20. Yuliana Astuti · 4 shared papers, 2022–2024 · strength 0.64
  21. Meirion Raymant · 4 shared papers, 2022–2024 · strength 0.64
  22. Jennifer P. Morton · 4 shared papers, 2022–2024 · strength 0.64
  23. Julia V. Mayerle · 10 shared papers, 2014–2021 · strength 0.62
  24. Phillip J. Hopley · 2 shared papers, 2026 · strength 0.61
  25. Bengt L. G. Glimelius · 8 shared papers, 2014–2025 · strength 0.57

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.